Obesity is spreading around the world and may contribute to a wide range of harmful conditions, such as cancer, diabetes, fatty liver, and cardiovascular disorders. Obesity can be caused by a variety of factors, such as a bad diet, insufficient rest or exercise, and heredity. Although altering one's lifestyle is still the most effective way to lose weight and improve metabolic symptoms, the use of some medical approaches shows abundant potential for individuals who cannot keep healthy routines or make behavioral modifications. Recent studies into the causes of obesity and the metabolic syndrome that it is associated with have revealed the importance of gut probiotics in the pathogenesis and control of obesity, but studies on the applications of probiotics for weight loss still need further exploration.
Fortunately, recent breakthroughs in next-generation sequencing techniques expedite the discovery of novel probiotics, which encourages researchers and offers them lots of opportunities to further investigate the diversity of new microbes. These new probiotics can also be called next-generation probiotics or live biotherapeutic products (LBPs). They are typically characterized by live microbes and are intended to have therapeutic or preventive effects in human disease. LBPs have demonstrated considerable promise in recent years for decreasing infection, triggering innate immune responses, and controlling gastrointestinal metabolism.
As a result, live biotherapeutic drug discovery for obesity has become increasingly important in clinical treatment and is going on heatedly around the world. A number of studies have been done to investigate and develop treatments for obesity using a variety of probiotics, such as Akkermansia muciniphila, Lactobacillus spp., and Bifidobacterium spp.
Compared to other marketed drugs, however, the safety assessment of anti-obesity live biotherapeutic products faces serious challenges due to their special properties and mode of action. Therefore, the analytical development and qualification of live biotherapeutic products are indispensable during the development of LBPs, including but not limited to microbial identification, biological safety testing, potency testing, and stability testing, all of which are available at Creative Biolabs with the possession of innovative technology and talented scientific minds who have extensive experience in this field.
Creative Biolabs, as a biotech CRO with extensive experience and a good reputation in the development of live biotherapeutic drugs, has provided a great number of high-quality probiotic products and a full set of services regarding analytic development and qualifications to global customers. In the future, the company will continue to optimize its services and products and strive to offer preferred services and products at the best price, promoting the discovery of live biotherapeutic drugs targeting a variety of diseases across the world.
